echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Small molecule targeted drug market of lung cancer is vast, and the annual sales of Kemena is over one billion

    Small molecule targeted drug market of lung cancer is vast, and the annual sales of Kemena is over one billion

    • Last Update: 2017-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [market analysis of chinapharma.com] according to data statistics, the market scale of small molecule targeted drugs used in lung cancer market in China was 3.23 billion yuan in 2015, with a compound growth rate of 22.6% from 2010 to 2015

    It is reported that as the main product of Beida pharmaceutical industry, exetane (Kemena) achieved a revenue of 1.035 billion yuan in 2016, with a year-on-year growth of 13.36% and a year-on-year growth of 31.46% in sales

    According to data statistics, in 2015, the market scale of small molecule targeted drugs for lung cancer market in China was 3.23 billion yuan

    At present, the three main products, exetane (Kemena), gefitinib (Iresa) and erlotinib (Troika), are suitable for the treatment of locally advanced or metastatic non-small cell lung cancer that has received chemotherapy and is not suitable for chemotherapy

    On April 6, Beida pharmaceutical released its 2016 annual report

    Its operating revenue was 1.035 billion yuan, an increase of 13.16% year on year

    The net profit attributable to shareholders of listed companies was 369 million yuan, an increase of 6.81% year on year

    As the main product of Beida pharmaceutical, exetane (Kemena) achieved a revenue of 1.035 billion yuan in 2016, with a year-on-year growth of 13.36% and a year-on-year growth of 31.46%

    This product also accounted for 99.98% of the total revenue of Beida pharmaceutical

    The growth of Kemena's sales is due to its success in the first batch of national drug price negotiation varieties, achieving a large market volume after the price reduction of 54%

    Due to the lag of market reaction, the increment of sales volume is still releasing, and the growth rate of sales revenue is lower than that of sales volume

    The inclusion of the new medical insurance catalogue in 2017 will also be conducive to the market sales of Kemena in the future

    Although Kemena's annual sales exceeded 1 billion yuan, the domestic non-small cell lung cancer market has changed

    Domestic and foreign enterprises, including AstraZeneca, Roche, Bi and Qilu, have also "sharpened their swords" to prepare for the war

    According to data statistics, the market scale of small molecule targeted drugs for lung cancer market in China in 2015 was 3.23 billion yuan, with a compound growth rate of 22.6% from 2010 to 2015

    At present, the three main products, exetane, gefitinib and erlotinib, are suitable for the treatment of locally advanced or metastatic non-small cell lung cancer that has received chemotherapy and is not suitable for chemotherapy

    Eliza was approved by FDA in 2003 and listed in China in 2005

    It has been a high market share drug of EGFR-TKI in China

    In 2015, gefitinib's sales volume in China was 1.243 billion yuan, accounting for 38.5% of China's EGFR-TKI market share

    In 2015, gefitinib's global sales volume was 643 million dollars

    However, the market competition pattern is undergoing new changes, and more and more global giants are using new product intentions to share the market and re divide the sphere of influence

    On March 17, Boehringer Ingelheim announced in Guangzhou that the second generation irreversible TKI (tyrosine kinase inhibitor) targeting drug afatinib, which is currently on the market in the world, has officially entered the Chinese market

    Afatinib has been approved for treatment of EGFR mutation positive NSCLC patients in more than 70 countries, and has become the target drug of EGFR in many countries

    In addition, the drug was approved by the FDA and the European Union in 2016 to treat patients with advanced lung squamous cell carcinoma undergoing platinum chemotherapy or worsening after chemotherapy

    In April 2016, afatinib was included in the CFDA's priority approval process

    On March 24, AstraZeneca announced that CFDA approved the listing of its third generation of targeted lung cancer treatment drug Teresa (oxitinib mesylate) in China

    It is not only the third generation of oral, irreversible and selective EGFR mutation inhibitors listed in the world, but also the tumor drug approved in China for egfrt790m mutation positive local advanced or metastatic non-small cell lung cancer, and it is more It has set a record of the speed of listing of imported drugs in China after the implementation of chemical drug registration and classification in 2007

    Although the market share of gefitinib is gradually shrinking with the increase of sales of exetinib

    However, with the listing of Teresa, it will continue to form an offensive posture against Kemena

    The external prediction of AstraZeneca is that through the price reduction of Iresa, it is used to go low-end and fight against competitors, while Teresa is used to seize the market and form a pincer attack

    Erlotini (Troika) was also selected into the national drug price negotiation list with Kemena

    Although he finally chose to withdraw from the negotiation, in August 2016, Roche announced to reduce the price of Troika by 30% on the basis of the terminal retail price of 2358 yuan / box (10 day consumption)

    After being included in the national medical insurance catalogue, the price of Kemena is 1399 yuan / box (7-day consumption), and after the price reduction of troika, its price advantage is also shrinking

    In addition to these listed products, in recent years, with the increasing incidence rate of lung cancer, the demand for anti-cancer drugs in the field of domestic enterprises is increasing, and the investment in the field of anti-tumor drugs is gradually increasing

    At present, at least 25 companies in China are applying for the imitation of gefitinib, and at least 28 companies are applying for the imitation of erlotinib, among which there are some powerful enterprises such as Hengrui pharmaceutical, Luoxin pharmaceutical, Xiansheng pharmaceutical, etc

    At the end of 2016, Yirui, the first generic drug of gefitinib developed by Qilu Pharmaceutical Co., Ltd., was approved by CFDA to hold the humanities number of listing license, becoming a pilot drug of China's drug listing license holder system, and officially launched in February this year

    What attracts people's attention is the price of IRICO, which is down from 5000 yuan per box to 2000 yuan

    For Beida, the competition of NSCLC in China will be more fierce in the future

    Beida said that in 2017, it will actively promote the convergence of Kemena's medical insurance in all provinces and cities across the country, take core market areas as the basic point, further develop new markets and tap market potential

    Increase the academic promotion and brand building of Kemena, and effectively transform its product advantages into market advantages and brand advantages

    At the same time, actively expand the overseas market, including the export of ektini and the transfer of overseas rights and interests of research projects, and accelerate the company's internationalization process and overseas market layout.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.